Urgent Need for Improved Alzheimer's Management

The launch of ACCESS-AD comes at a critical juncture in Alzheimer’s disease management across Europe. Despite recent approvals of antibody-based disease-modifying therapies (DMTs), significant obstacles remain, including issues with diagnosis, patient stratification, and monitoring capabilities.

• The prevalence of Alzheimer's is projected to exceed 19 million individuals in Europe by 2050.
• There is an urgent need for scalable therapeutic options that can operate independently of high-intensity healthcare infrastructures.

Evaluating Blarcamesine: A Precision Medicine Approach

As a key part of the ACCESS-AD consortium, Anavex will evaluate blarcamesine, an investigational oral therapy targeting autophagy via SIGMAR1 activation. This therapy aims to restore cellular function and slow the neurodegenerative processes associated with Alzheimer’s disease.

ACCESS-AD's framework is designed to facilitate:

• Advanced neuroimaging techniques.
• Blood-based biomarker assessments.
• Digital measures and AI-driven decision support systems.

This approach supports early detection and the safe implementation of innovative treatments.

Integrating Blarcamesine into European Healthcare Systems

The integration of blarcamesine into ACCESS-AD’s research provides a unique opportunity to generate predictive clinical insights. By utilizing standardized imaging and biomarker data alongside digital health information, the study aims to identify:

• Patient characteristics that predict treatment responses.
• Real-world feasibility of blarcamesine in both specialized and community clinical settings.

This aligns with Anavex's ongoing commitment to advancing precision medicine that incorporates comprehensive clinical and genomic data.

Quotes from Leadership

Christopher U. Missling, PhD, President and CEO of Anavex, expressed enthusiasm about the collaboration: “We are pleased that blarcamesine will be evaluated within ACCESS-AD’s innovative precision-medicine framework. This initiative represents a unique opportunity to integrate advanced biomarker data and digital tools with a therapy that is intentionally designed to be accessible, scalable, and compatible within diverse healthcare environments.”

Understanding Alzheimer's Disease

Alzheimer's disease is the predominant cause of dementia, accounting for 60-80% of all dementia cases globally. It is a progressive disorder characterized by a decline in memory and cognitive abilities, significantly impacting individuals' daily lives. The pressing need for new treatment options cannot be overstated, as effective therapies could greatly alleviate the burden on patients and society alike.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company focused on developing novel therapeutics for neurodegenerative and neuropsychiatric disorders, including Alzheimer's disease. Their lead candidate, ANAVEX®2-73 (blarcamesine), has shown promising results in various clinical trials targeting AD and other conditions, emphasizing its potential as a transformative therapeutic option in the CNS space.

Forward-Looking Statements

This announcement contains forward-looking statements, which involve inherent risks and uncertainties. Actual outcomes may differ significantly from projections, and readers are encouraged to review Anavex's latest Annual Report on Form 10-K filed with the SEC for more detailed disclosures regarding risks.

Contact Information

For further information, contact:

• Anavex Life Sciences Corp. Research & Business Development
  Email: info@anavex.com
• Investors: Andrew J. Barwicki, Investor Relations
  Tel: 516-662-9461
  Email: andrew@barwicki.com